Results 311 to 320 of about 1,905,672 (358)

Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy

BJU International, 2020
To evaluate risk of prostate cancer biochemical recurrence (BCR) after radical prostatectomy (RP) in men receiving vs not receiving testosterone replacement therapy (TRT).
T. Ahlering, Linda My Huynh, M. Towe, K. See, J. Tran, K. Osann, F. el Khatib, F. Yafi   +7 more
semanticscholar   +1 more source

Salvage radiotherapy for biochemical recurrence after radical prostatectomy

BJU International, 2005
OBJECTIVE To evaluate the clinical outcome of salvage radiotherapy (RT) for biochemical recurrence after radical prostatectomy (RP) at our institution. PATIENTS AND METHODS Between March 1999 and January 2004, 37 patients had salvage ...
Akito, Terai, Yoshiyuki, Matsui, Koji, Yoshimura, Yoichi, Arai, Yoshihiro, Dodo   +4 more
openaire   +2 more sources

Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score

Journal of Magnetic Resonance Imaging, 2020
Biochemical recurrence (BCR) affects a significant proportion of patients who undergo robotic‐assisted laparoscopic prostatectomy (RALP).
I. Jambor, U. Falagario, P. Ratnani, I. Perez, K. Demir, H. Merisaari, S. Sobotka, G. K. Haines, A. Martini, A. Beksac, S. Lewis, T. Pahikkala, P. Wiklund, S. Nair, A. Tewari   +14 more
semanticscholar   +1 more source

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

Clinical Nuclear Medicine, 2019
PURPOSE One of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established Ga-PSMA, a novel promising PET tracer in PCa imaging is F-fluciclovine.
B. Pernthaler, Roman Kulnik, C. Gstettner, S. Salamon, R. Aigner, H. Kvaternik   +5 more
semanticscholar   +1 more source

Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis

Journal of Clinical Microbiology, 1992
Because so little is known about the pathogenesis of recurrent bacterial vaginosis (BV), a longitudinal microbiological study was conducted on 13 women with recurrent BV treated sequentially with conventional metronidazole therapy. A rapid clinical response characterized by disappearance of mal odor and an improvement in vaginal discharge occurred in ...
R L, Cook, V, Redondo-Lopez, C, Schmitt, C, Meriwether, J D, Sobel   +4 more
openaire   +2 more sources

Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?

AJR. American journal of roentgenology, 2020
OBJECTIVE. In this article, we discuss the evolving roles of imaging modalities in patients presenting with biochemical recurrence after prostatectomy. CONCLUSION.
P. Bhargava, G. Ravizzini, B. Chapin, V. Kundra   +3 more
semanticscholar   +1 more source

Biochemical Recurrence: A Valuable Endpoint?

2013
Clinically relevant outcomes such as distant metastases and death from prostate cancer do not occur for many years after definitive treatment for localized prostate cancer. In view of the long natural history of prostate cancer, the identification and validation of surrogate endpoints that can be measured earlier and correlate with clinical progression
openaire   +1 more source

Updates on Management of Biochemical Recurrent Prostate Cancer

Current Treatment Options in Oncology
Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical. Patients with high-risk features such as PSA doubling time (PSADT) ≤ 9-12 months warrant earlier imaging for metastasis detection and consideration for intensified therapy (beyond intermittent androgen ...
Lauren Folgosa, Cooley, Abhishek, Srivastava, Neal D, Shore   +2 more
openaire   +2 more sources

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases, 2022
A. Pozdnyakov, R. Kulanthaivelu, G. Bauman, C. Ortega, P. Veit-Haibach, U. Metser   +5 more
semanticscholar   +1 more source

Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma

Thyroid, 2019
Background: Expression of the programmed death-ligand 1 (PD-L1) in medullary thyroid carcinoma (MTC) has been rarely reported. In this study, we evaluated PD-L1 positivity in MTC and analyzed its correlation with clinicopathological characteristics ...
Xiao Shi, Peng-cheng Yu, Bo-Wen Lei, Cui-Wei Li, Yan Zhang, Li-Cheng Tan, R. Shi, Jie Wang, Ben Ma, Weibo Xu, X. Wang, Jiaqian Hu, N. Huang, Wenjun Wei, Yu Wang, Tongzhen Chen, Yu‐Long Wang, Q. Ji   +17 more
semanticscholar   +1 more source